
    
      This is a multi-center, prospective, randomized, placebo-controlled trial. A total of 201
      participants were enrolled and randomly assigned to gemigliptin 50 mg daily and standard care
      of diabetes mellitus for 6 months. The changes of coronary calcium score (CAC score),
      cardio-ankle vascular index (CAVI), estimated glomerular filtration rate (GFR), markers of
      vascular calcification and markers of tubular renal injury were evaluated at baseline and 6
      months.
    
  